RT Journal Article
SR Electronic
T1 High Efficacy of Chemoradiation Therapy Sensitized by Weekly Docetaxel for Anaplastic Thyroid Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3445
OP 3448
VO 33
IS 8
A1 NAOYOSHI ONODA
A1 SHINICHIRO KASHIWAGI
A1 SATORU NODA
A1 HIDEMI KAWAJIRI
A1 TSUTOMU TAKASHIMA
A1 TETSURO ISHIKAWA
A1 KOSEI HIRAKAWA
YR 2013
UL http://ar.iiarjournals.org/content/33/8/3445.abstract
AB Background: Although rare, treatment of anaplastic thyroid carcinoma (ATC) is very difficult due to its aggressiveness and resistance to therapeutic efforts. Patients and Methods: We reviewed outcomes for six patients who underwent a unique chemoradiotherapy regimen consisting of external irradiation (45 to 60 Gy) combined with concurrent low-dose weekly docetaxel administration at 10 mg/m2. Results: The scheduled treatment was completed and showed local disease control in all patients. Two patients showed complete response lasting for 166 and 257 days, three patients showed partial response for 58, 107 and 194 days, and one showed stable disease for 382 days. Overall, patients treated with this chemoradiotherapy survived from 86 to 1,901 days with additional systemic chemotherapy. No toxicities over grade 3 were observed. Conclusion: This chemoradiotherapy is useful for locoregional control of ATC, while offering acceptable toxicity. The effect lasted temporally but long enough to maintain patients' quality of life for this highly aggressive malignancy.